ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1915

Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

Brian Coburn1, Michael George1, Joshua Baker1, Jesse Hsu2, Qufei Wu1, Lang Chen3, Fenglong Xie3, Huifeng Yun4 and Jeffrey Curtis5, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama Birmingham, Birmingham, AL, 5Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, glucocorticoids, Myocardial Infarction, rheumatoid arthritis, Stroke

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Heart & Lung (1915–1918)

Session Type: Abstract Session

Session Time: 2:00PM-2:15PM

Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term. In this study we evaluated the cardiovascular risk of long-term, low-dose glucocorticoid use by studying patients on stable DMARD treatments.

Methods: Using Medicare claims and Optum’s deidentified Clinformatics Data Mart from 2006 to 2015, we identified patients with RA (2 diagnosis codes ≥7 days apart) who remained on stable DMARD therapy for >180 days (no gaps >90 days and no new DMARDs), excluding patients with previous myocardial infarction (MI), stroke, coronary artery bypass grafting, or percutaneous coronary intervention using all available data during or prior to the baseline period. The 180 days before DMARD initiation and the first 180 days of stable DMARD course comprised the baseline period. Average glucocorticoid dose was assessed during the final 90 days of the baseline period and categorized as none, ≤5mg, 5-10mg, or >10mg/day. Inverse probability weights for the likelihood of being prescribed each glucocorticoid dose category were constructed using multinomial logistic regression. Cause-specific proportional hazards models with inverse probability weights and clustering to account for patients with multiple treatment periods were used to estimate the effect of glucocorticoid use on composite cardiovascular outcomes (stroke or MI). Patients were censored at the end of the stable DMARD course, end of enrollment, 9/30/2015, death in Medicare data, or 90 days after a change in glucocorticoid dose category (the completion of a treatment period). Predicted 1-year incidence of events was calculated from the weighted models to estimate risk by glucocorticoid dose while controlling for confounding factors.

Results: There were 188,940 treatment periods among 135,583 patients in Medicare and 51,295 treatment periods among 39,272 patients in Optum (Table 1). Medicare patients had 158,839 years at risk with 2,067 composite cardiovascular outcomes and Optum patients had 36,876 years at risk with 313 outcomes corresponding to an incidence of 1.3 and 0.8 per 100 person-years, respectively. In Medicare, glucocorticoids were associated with a dose-dependent increase in cardiovascular risk in weighted models (Table 2) with predicted 1-year incidence of 1.4% (95% CI 1.2-1.6) for ≤5mg, 1.7% (1.4-2.0) for 5-10mg, and 1.9% (1.3-2.7) for >10mg versus 1.1% for no glucocorticoids (Figure 1). Unadjusted results were similar in the younger Optum population, but adjusted results were not significant with predicted 1-year incidence of 0.9% (95% CI 0.7-1.1), 0.8% (0.5-1.2), and 0.8% (0.4-1.8), respectively, versus 0.7% with no glucocorticoids.

Conclusion: Among older RA patients on stable DMARD therapy, long-term use of low-dose glucocorticoid was associated with increased risk for stroke or MI. Higher doses of glucocorticoids were associated with even greater risk. The absolute risk in the younger Optum cohort was lower and research with larger patient populations will be needed to determine if risks exist among younger patients with lower baseline cardiovascular risk.

Values are in the format: mean (standard deviation), n (%), or median [interquartile-range]

Hazard ratios (HR) and confidence intervals (CI) are from unadjusted cause-specific proportional hazard models and from propensity adjusted models using stabilized inverse probability weights (IPWS). * Incidence per 100 person-years

Predicted 1-year incidence of myocardial infarction or stroke calculated from inverse probability weighted cause-specific hazards models. Hazard ratios for these models are shown in Table 2. * NNH = number needed to harm. The NNH 95% confidence intervals (CI) for each glucocorticoid dose category in the Optum dataset overlaps with the reference estimate for no glucocorticoids. Negative estimates can be interpreted as the number needed to treat to avoid a composite cardiovascular outcome.


Disclosures: B. Coburn, None; M. George, None; J. Baker, Bristol-Myers Squib, 2, Pfizer, 2; J. Hsu, None; Q. Wu, None; L. Chen, None; F. Xie, None; H. Yun, Pfizer, 5; J. Curtis, AbbVie, 2, Amgen, 2, 5, Bristol-Myers Squibb, 2, Janssen, 2, Eli Lilly, 2, Myriad, 2, Pfizer Inc, 2, 5, Roche/Genentech, 2, UCB, 2, CorEvitas, 2, 5, Crescendo Bio, 5.

To cite this abstract in AMA style:

Coburn B, George M, Baker J, Hsu J, Wu Q, Chen L, Xie F, Yun H, Curtis J. Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-with-low-dose-glucocorticoids-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-with-low-dose-glucocorticoids-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology